Preeti Kharel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Preeti Kharel has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bharosha Bhattarai
Penn State Hershey Medical Center, PA, USA
1 shared publication - Bibhusan Basnet
Healthy Info Charlotte North Carolina USA
1 shared publication Dipendra Kandel
Gandaki Medical College Teaching Hospital and Research Center, Pokhara, Nepal
1 shared publication- Gauri Adhikari
Washington University/Consortium at Missouri Baptist Medical Center, St. Louis, MO, USA
1 shared publication - Naveen Gautam
Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
1 shared publication - Prabha Bhandari
Kathmandu University School of Medical Sciences, Dhulikhel, Nepal
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (10) , 6708-6717
Digital and algorithmic strategies for guideline-directed medical therapy initiation and up-titration in adults with heart failure with reduced ejection fraction: a systematic review
Background: Guideline-directed medical therapy (GDMT) reduces morbidity and mortality in heart failure with a reduced ejection fraction (HFrEF), yet underuse and suboptimal up-titration remain common. Digital and algorithmic strategies are increasingly being used to address these gaps, but their comparative effectiveness remains uncertain. Methods: This systematic review followed the PRISMA 2020 guidance and was prospectively registered with PROSPERO (CRD420251268580). PubMed, Embase, and Scopus were searched from inception through 26 December 2025. Randomized and comparative studies enrolling adults with HFrEF were eligible if they evaluated digital, algorithm-based, or telemonitoring strategies designed to facilitate GDMT initiation, titration, or optimization versus usual care. Results: Six randomized comparative trials involving 3706 participants were included. Interventions comprised provider-facing electronic health record alerts and digitally enabled remote titration or telemonitoring pathways. Five of the six trials showed improvements in medication-optimization outcomes; the single neutral trial was a provider-facing alert intervention that showed no difference in GDMT prescribing at hospital discharge. Remote pathway-based strategies demonstrated the largest effects, including higher titration completion (82.1% vs 53.8% at 6 months; an absolute difference of approximately 28 percentage points) and greater improvements in therapy scores. Alert-based interventions showed mixed findings, including no difference in overall GDMT class prescribing at discharge in one inpatient trial (34% vs 34%). Meta-analysis was not performed because of substantial heterogeneity in interventions, outcomes, and reporting formats. Conclusion: Digital strategies appear to improve GDMT optimization in HFrEF, particularly when embedded within structured care pathways that enable repeated reassessment and protocol-driven titration. Passive alerts alone appear less effective. Standardized outcome measures and trials evaluating clinical endpoints are needed.
- 10 September 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (10) , 6708-6717
Open AccessDigital and algorithmic strategies for guideline-directed medical therapy initiation and up-titration in adults with heart failure with reduced ejection fraction: a systematic review
Background: Guideline-directed medical therapy (GDMT) reduces morbidity and mortality in heart failure with a reduced ejection fraction (HFrEF), yet underuse and suboptimal up-titration remain common. Digital and algorithmic strategies are increasingly being used to address these gaps, but their comparative effectiveness remains uncertain. Methods: This systematic review followed the PRISMA 2020 guidance and was prospectively registered with PROSPERO (CRD420251268580). PubMed, Embase, and Scopus were searched from inception through 26 December 2025. Randomized and comparative studies enrolling adults with HFrEF were eligible if they evaluated digital, algorithm-based, or telemonitoring strategies designed to facilitate GDMT initiation, titration, or optimization versus usual care. Results: Six randomized comparative trials involving 3706 participants were included. Interventions comprised provider-facing electronic health record alerts and digitally enabled remote titration or telemonitoring pathways. Five of the six trials showed improvements in medication-optimization outcomes; the single neutral trial was a provider-facing alert intervention that showed no difference in GDMT prescribing at hospital discharge. Remote pathway-based strategies demonstrated the largest effects, including higher titration completion (82.1% vs 53.8% at 6 months; an absolute difference of approximately 28 percentage points) and greater improvements in therapy scores. Alert-based interventions showed mixed findings, including no difference in overall GDMT class prescribing at discharge in one inpatient trial (34% vs 34%). Meta-analysis was not performed because of substantial heterogeneity in interventions, outcomes, and reporting formats. Conclusion: Digital strategies appear to improve GDMT optimization in HFrEF, particularly when embedded within structured care pathways that enable repeated reassessment and protocol-driven titration. Passive alerts alone appear less effective. Standardized outcome measures and trials evaluating clinical endpoints are needed.
- 2 July 2025
- Published by ehealthyinfo in The American Journal of Patient Health Info
- Vol. 2 (3)
Obesity | Causes, Treatments and Anti-Obesity Medications
People who are overweight have a higher chance of getting serious diseases like heart problems, diabetes, and cancer. These sicknesses cause millions of deaths every year. Weight loss takes time and starts with eating healthy foods and moving your body more. Weight-loss medicines, when used with healthy habits, can help people lose 5% to 21% of their starting weight. GLP-1 medications, including Ozempic and Mounjaro, are among the most effective drugs for managing obesity. GLP-1s are expensive, are usually not paid for by insurance, and are meant to be taken for the rest of your life.
- 2 July 2025
- Published by ehealthyinfo in The American Journal of Patient Health Info
- Vol. 2 (3)
Obesity | Causes, Treatments and Anti-Obesity Medications
People who are overweight have a higher chance of getting serious diseases like heart problems, diabetes, and cancer. These sicknesses cause millions of deaths every year. Weight loss takes time and starts with eating healthy foods and moving your body more. Weight-loss medicines, when used with healthy habits, can help people lose 5% to 21% of their starting weight. GLP-1 medications, including Ozempic and Mounjaro, are among the most effective drugs for managing obesity. GLP-1s are expensive, are usually not paid for by insurance, and are meant to be taken for the rest of your life.
- 4 April 2025
- Published by ehealthyinfo in The American Journal of Patient Health Info
- Vol. 2 (2)
Crohn’s Disease | Causes, Diagnosis & Treatment
Crohn’s disease is an inflammatory bowel disease that can affect any part of the digestive tract, with the small intestine and colon being the most commonly affected areas. Crohn’s disease persists throughout life and follows a pattern of relapses and periods of improvement. While the exact cause of inflammatory bowel disease remains unclear, evidence suggests it stems from an abnormal immune response in the gut triggered by environmental factors like drugs, toxins, infections, or gut microbes in individuals with certain genetic susceptibilities. Smokers have a higher risk of developing Crohn's disease than nonsmokers. To better manage Crohn's disease, try increasing fluid intake, eating smaller, more frequent meals, and maintaining a food diary to identify possible triggers.
- 4 April 2025
- Published by ehealthyinfo in The American Journal of Patient Health Info
- Vol. 2 (2)
Crohn’s Disease | Causes, Diagnosis & Treatment
Crohn’s disease is an inflammatory bowel disease that can affect any part of the digestive tract, with the small intestine and colon being the most commonly affected areas. Crohn’s disease persists throughout life and follows a pattern of relapses and periods of improvement. While the exact cause of inflammatory bowel disease remains unclear, evidence suggests it stems from an abnormal immune response in the gut triggered by environmental factors like drugs, toxins, infections, or gut microbes in individuals with certain genetic susceptibilities. Smokers have a higher risk of developing Crohn's disease than nonsmokers. To better manage Crohn's disease, try increasing fluid intake, eating smaller, more frequent meals, and maintaining a food diary to identify possible triggers.